Evaluation of the Association between Lithium Treatment and GSK-3 beta Polymorphism in Bipolar Disorder Patients

ALTINBAŞ K., Yesilbas D., Ince B., Cansiz A., SILAN F., ÖZDEMİR Ö., ...More

TURK PSIKIYATRI DERGISI, vol.29, no.2, pp.73-78, 2018 (SSCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 29 Issue: 2
  • Publication Date: 2018
  • Doi Number: 10.5080/u20582
  • Journal Indexes: Social Sciences Citation Index (SSCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.73-78
  • Çanakkale Onsekiz Mart University Affiliated: Yes


Objective: There is a lack of evidence regarding clinical predictors for the treatment response to lithium, which is the main stay treatment option for bipolar disorder. Studies that examined the mechanistic action of lithium revealed that glycogen synthase kinase 3 beta (GSK-3 beta) enzymeinhibition was important in regard to treatment responses. Based on this background, we aimed to investigate the association between responses to lithium treatment and five different polymorphisms of GSK-3 beta.